Como se combate o populismo? "Com eleições", responde Fukuyama

[Marco]

Por fundamentais, não vamos lá!
É um perfeito tiro no escuro.

Por AT, temos sempre aquela velha teoria do fecho de GAPs, que a acontecer aqui, daria um ganho muito interessante, pois há uma GAP acima, bem acima, como é visível no Gráfico do post anterior!

Obrigado pela vossa colaboração, fiquei esclarecido!

[cayenne]

isto é um bilhete de lotaria, ou vai à falência ou dá montes de dinheiro.

não é um investimento

totalmente de acordo
estive a fazer um pouco de reaserch na net e as opiniões dos analistas apontam nesse sentido
"An american PAD"

[Visitante]

isto é um bilhete de lotaria, ou vai à falência ou dá montes de dinheiro.

não é um investimento

[Alfred E. Neuman]

Genta's on the Ropes

By Charly Travers
November 9, 2004


I thought things were looking bad for Genta (Nasdaq: GNTA) back in May when the Food and Drug Administration's oncologic drugs advisory committee said it could not recommend Genasense for treating melanoma, given that the drug's benefits did not outweigh its toxicity. On that news, Genta's stock took a 70% hit.

Last night, the other shoe dropped. Aventis (NYSE: AVE) was Genta's partner for Genasense, but now that agreement has dissipated, with Aventis packing up and going home. It is never, ever a good sign when a pharmaceutical partner leaves. As a result, Genta's stock opened down 40% this morning and is now down 85% for the year. Ouch!


Genta tried to take the edge off of this blow by announcing top-line results from the phase 3 trial in chronic lymphocytic leukemia (CLL). While there was a benefit in adding Genasense to chemotherapy in complete or partial remissions, there was no improvement in patient survival or time-to-disease progression. Full data will be released at the American Society of Hematology meeting next month. An important piece of info revealed during the conference call this morning was that Aventis saw this data prior to ending the partnership. That leads to the question: Would Aventis have bailed out if it thought Genasense was going to be a successful drug in the treatment of CLL? Probably not.


There are financial ramifications to Aventis' exit. At the end of its third quarter, Genta had $36.7 million cash on hand. Genta had a line of credit with Aventis and now owes Aventis $19 million by May 2005. So the company really has only $17.7 million to work with. That's a dicey situation. It's not easy to raise funds on good terms with a stock under $2. Especially when the only drug under development is of dubious value because of toxicity and efficacy concerns.

[Marco]

Digam algo, pois gostaria de tentar perceber o fenómeno para ver se o investimento wm tal farmacêutica, valerá ou não a pena!

O que provocou aquela queda violenta, em Abril-Maio de 2004, bem visivel no gráfico, em que em poucos dias fez a cotação cair dos 16 aos 2 dólares!!!???

Gráfico1:
http://finance.yahoo.com/q/bc?s=GNTA&t= ... z=m&q=l&c=

Gráfico2:
http://finance.yahoo.com/q/bc?s=GNTA&t=my